, Volume 162, Issue 21-22, p 453
Date: 19 Nov 2012


This is an excerpt from the content

The term “biomarker” is broadly used and covers a broad range of parameters. In a definition from a working group of the National Institute of Health (2001) it is described as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention”.

Biomarkers may be used for screening, prognosis, prediction or stratification of response to therapy, or monitoring of disease and course of therapy.

In autoimmune diseases, a multitude of biomarkers, e.g. auto-antibodies, may evolve and call for instrumental and administrable algorithms guiding the general practitioner to a precise diagnosis at an early stage. Such an approach is presented in the paper from Endler et al., providing a bridge from clinical symptoms suspicious for autoimmune rheumatoid disorders to diagnosis and, later on, monitoring of therapy.

A similar complexity is addressed in the paper of Bieglmayer et al.,